Oculo
Category: AI in Healthcare
An AI-powered platform for digital therapeutics, focusing on inflammation and mental health. Oculo was founded in 2022. The company is led by Dr. Srirupa Das. Based in Cambridge, Massachusetts, USA. Team size: N/A. Total funding raised: Not publicly available. Latest round: Acquisition, Undisclosed, 2025-09, led by Vyome Holdings. Key investors include Not publicly available.
- Founded
- 2022
- Headquarters
- Cambridge, Massachusetts, USA
- Team size
- N/A
- Total funding
- Not publicly available
Value proposition
To quantify mental processes and provide digital therapeutics at the intersection of mental health, psychoneuroimmunology, and digital health.
Products and solutions
AI Psychiatrist Platform
Unique value
Oculo is unique in its focus on the intersection of the human body and mind, using AI to quantify mental states and develop digital therapeutics for inflammation-related conditions.
Target customer
Patients with inflammatory conditions and mental health issues, and healthcare providers.
Industries served
Healthcare, Digital Therapeutics
Technology advantage
As an MIT AI spinout, Oculo's advantage lies in its advanced AI capabilities to analyze the connection between mental health and physical inflammation, creating a new category of therapeutics.
How they differentiate
Oculo is developing an AI-powered platform to create a digital psychiatrist focused on inflammation-related diseases. This positions them at the intersection of AI, mental health, and immunology, a unique niche compared to broader mental health chatbots or general digital therapeutics platforms.
Main competitors
Woebot Health, Wysa, Biofourmis
Key partnerships
Vyome Holdings (Acquirer)
Notable customers
Not publicly available
Major milestones
Spin-out from Massachusetts Institute of Technology (MIT), Acquired by Vyome Holdings to form a new AI-focused business unit for developing digital therapeutics.
Growth metrics
Not publicly available
Market positioning
Oculo is an early-stage, research-driven startup in the digital therapeutics and healthcare AI market. After its acquisition by Vyome, a clinical-stage healthcare company, it is positioned to integrate its AI technology to develop targeted digital therapeutics for inflammation-related conditions.
Geographic focus
United States
Patents and IP
Information not publicly available
About Dr. Srirupa Das
Co-founder of Oculo, with a background in AI and healthcare.
Official website: https://www.oculolabs.org/